Basic information Binding Mode Safety Supplier Related
ChemicalBook >  Product Catalog >  Biochemical Engineering >  Inhibitors >  Angiogenesis >  Syk inhibitors >  Fostamatinib

Fostamatinib

Basic information Binding Mode Safety Supplier Related

Fostamatinib Basic information

Product Name:
Fostamatinib
Synonyms:
  • Fostamatinib
  • FostaMatinib DisodiuM
  • FostaMatinib (R788)
  • R788
  • NSC-745942
  • R-935788
  • R7935788
  • 6-[[5-Fluoro-2-[(3,4,5-trimethoxyphenyl)amino]-4-pyrimidinyl]amino]-2,2-dimethyl-4-[(phosphonooxy)methyl]-2H-pyrido[3,2-b]-1,4-oxazin-3(4H)-one
CAS:
901119-35-5
MF:
C23H26FN6O9P
MW:
580.46
EINECS:
618-473-2
Product Categories:
  • Inhibitors
  • API
Mol File:
901119-35-5.mol
More
Less

Fostamatinib Chemical Properties

Melting point:
214° - 217°C
Boiling point:
814.2±75.0 °C(Predicted)
Density 
1.496
storage temp. 
-20°C, Hygroscopic
solubility 
DMSO (Slightly), Methanol (Slightly)
pka
1.70±0.10(Predicted)
form 
Solid
color 
White to Off-White
Stability:
Hygroscopic
More
Less

Fostamatinib Usage And Synthesis

Binding Mode

As shown in the co-crystal structure of tamatinib-SYK (Fig. 1), the aminopyrimidine moiety forms two hydrogen bonds with Ala451 of the hinge region. In addition, there is an atypical hydrogen bond (CH...O=C) between CH at 6 and amide carbonyl of Glu449 (Fig. 2).

Uses

Fostamatinib can be used to treat cancers that have acquired resistance to kinase inhibitors.

Indications

Fostamatinib is an FDA-approved first-in-class spleen tyrosine kinase (SYK) inhibitor, specifically indicated for the treatment of adult patients with chronic immune thrombocytopenia (ITP) who have not responded adequately to prior therapies.

brand name

Tavalisse

General Description

Class: non-receptor tyrosine kinase; Treatment: ITP; Other name: R788; Oral bioavailability = 100% (prodrug); Elimination half-life = 15 h (tamatinib); Protein binding = 98.3%

Biological Activity

fostamatinib is a small molecule inhibitor of spleen tyrosine kinase (syk) with ic50 value of 41nm [1].fostamatinib is an orally bioavailable prodrug of r406. it is developed for the treatment of autoimmune diseases. the effective metabolite of fostamatinib, r406, is an atp-competitive inhibitor of syk with ki value of 30nm. r406 also inhibits the activity of other kinases including flt3, lyn (ic50=63nm) and lck (ic50=37nm). it is found that r406 inhibits both bcr and fcr mediated responses in vitro. besides that, r406 also shows effects in other cells types and signalling pathways. in the in vivo assay, fostamatinib shows to be highly active to inhibit fcr-mediated signaling in various animal models of allergy, autoimmunity and inflammation. moreover, fostamatinib also exerts efficacy in sle animal models. treatment of fostamatinib suppresses the established renal and skin disease and reduces lymphadenopathy in the mrl/lpr strain [1].

target

Primary target: SYK

References

[1] mcadoo s p, tam f w k. fostamatinib disodium. drugs of the future, 2011, 36(4): 273.

FostamatinibSupplier

Anqing Runke Biomedical Technology Co., Ltd. Gold
Tel
0556-5282330 18075373931
Email
sales@growingchem.com
Chuzhou KeMail Chemical Technology Co., Ltd Gold
Tel
0550-5196001 15000891977
Email
wj520wjxby@126.com
CAREBIO PHARMA Gold
Tel
18501057619
Email
771737847@qq.com
Shanghai Boyle Chemical Co., Ltd.
Tel
Email
sales@boylechem.com
Chembest Research Laboratories Limited
Tel
+86-21-20908456
Email
sales@BioChemBest.com